Početna › Debljina › Tennessee
Kliničke studije za Debljina u državi Tennessee
38 studija za Debljina traži sudionike na lokacijama u državi Tennessee.
Gradovi u državi Tennessee
Službeni tekst studije (engleski)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Holston Medical Group - Bristol /ID# 282045, Bristol
- New Phase Research & Development /ID# 282131, Knoxville
- Summit Medical Group- Halls Family Physicians /ID# 282435, Knoxville
- i još 1
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT07752979AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- M3 Wake Research Chattanooga, Chattanooga
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07533175A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- LifeDoc Health, Memphis
U tijeku regrutacijaFaza 3
Od 8 do 18 godina · Oba spola · Ažurirano 30. ruj 2026. · NCT07253285Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- AMR Clinical, Nashville
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT07837973Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastroenterology Center Of The Midsouth, Cordova
U tijeku regrutacijaFaza 3
Od 18 do 70 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Vanderbilt Health One Hundred Oaks, Nashville
U tijeku regrutacijaFaza 3
Od 6 do 17 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastroenterology Center Of The Midsouth, Cordova
U tijeku regrutacijaFaza 3
Od 18 do 70 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06937086A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Franklin
- Research Site, Jackson
- Research Site, Knoxville
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Stern Cardiovascular Foundation Inc, Germantown
- Accellacare of Knoxville, Knoxville
- Cardiovascular Research of Knoxville North Knoxville Medical Center, Powell
- i još 1
U tijeku regrutacijaFaza 3
Od 45 do 99 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- AMR Clinical, Nashville
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Quality Medical Research, Nashville
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07589608Transition to Ambulatory Bariatric Surgery (TABS) Trial
- Vanderbilt University Medical Center, Nashville
U tijeku regrutacija
Od 25 do 55 godina · Oba spola · Ažurirano 21. ruj 2026. · NCT07011628A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Memphis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Memphis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Apex Research Foundation, LLC, Jackson
- The Jackson Clinic PA, Jackson
- Parkway Cardiology Associates, Oak Ridge
- i još 2
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 16. ruj 2026. · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Innovative Clinical Research, Clarksville
- Clinical Research Associates, Nashville
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Nashville
U tijeku regrutacijaFaza 3Zdravi dobrovoljci dobrodošli
Od 18 do 79 godina · Oba spola · Ažurirano 11. ruj 2026. · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Quality Medical Research, Nashville
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 8. ruj 2026. · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- DelRicht Research - Thompson's Station, Smyrna
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailea Clinical Site, Memphis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- New Phase Research and Development, Knoxville
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 3. ruj 2026. · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Chattanooga
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07284875The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
- Vanderbilt University Medical Center, Nashville
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 1. ruj 2026. · NCT05972564A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Kingsport
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT07784725A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Balad Hlth Sys-Welmont CardCVA, Greeneville
- The Jackson Clinic, PA, Jackson
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Knoxville
U tijeku regrutacijaFaza 3
Od 18 do 79 godina · Oba spola · Ažurirano 10. kol 2026. · NCT07654361Atomoxetine in Melanocortin Obesity Syndrome
- Vanderbilt University Medical Center, Nashville
U tijeku regrutacijaFaza 2
Od 6 godina i više · Oba spola · Ažurirano 7. kol 2026. · NCT06899178A Study to Improve Skeletal Muscle in Veterans With HIV
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
U tijeku regrutacija
Od 20 do 80 godina · Muškarci · Ažurirano 26. lip 2026. · NCT06845046Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
- Holston Medical Group_Bristol, Bristol
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 25. lip 2026. · NCT07607587Daily Eating Patterns for Total Health Study
- Healthy Eating and Activity Laboratory, Knoxville
U tijeku regrutacija
Od 25 do 60 godina · Oba spola · Ažurirano 15. lip 2026. · NCT06455995A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
- MBX Biosciences Investigational Site, Knoxville
U tijeku regrutacijaFaza 1
Od 18 do 65 godina · Oba spola · Ažurirano 9. lip 2026. · NCT07142707EBT Fruit and Vegetable Prescription
- Cherokee Health Systems, Dameron Avenue Pedatrics, Knoxville
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 4 do 10 godina · Oba spola · Ažurirano 9. lip 2026. · NCT05028205Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
- St. Jude Children's Research Hospital, Memphis
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 4. lip 2026. · NCT07228741Metabolic Effects of Angiotensin-(1-7)
- Vanderbilt University Medical Center, Nashville
U tijeku regrutacijaFaza 1
Od 18 do 60 godina · Oba spola · Ažurirano 22. svi 2026. · NCT02646475Sympathetic Mechanisms in Obesity-Crossover Design
- Vanderbilt University Medical Center, Nashville
U tijeku regrutacijaFaza 1/2
Od 18 do 65 godina · Oba spola · Ažurirano 27. velj 2026. · NCT05312892A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
- Vanderbilt University Medical Center (Part C only), Nashville
U tijeku regrutacijaFaza 1/2Zdravi dobrovoljci dobrodošli
Od 12 do 65 godina · Oba spola · Ažurirano 22. pro 2025. · NCT06239116Tirzepatide in PWS, HO and GNSO
- Vanderbilt University Medical Center, Nashville
U tijeku regrutacijaFaza 4
Od 18 do 26 godina · Oba spola · Ažurirano 16. ruj 2025. · NCT06901245Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia
- University of Tennessee Medical Center, Knoxville
U tijeku regrutacijaOpažajna studija
Od 18 do 45 godina · Žene · Ažurirano 10. ruj 2025. · NCT06802861Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.